Related Experiment Video
Updated: Jul 4, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
[Current immune therapy for Alzheimer's disease]
T Grimmer1, R Perneczky, A Kurz
1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Zentrum für kognitive Störungen, Technische Universität, Möhlstrasse 26, 81675 München. t.grimmer@lrz.tum.de
Der Nervenarzt
|June 11, 2008
Summary
New Alzheimer's disease treatments target the neurodegenerative process by inhibiting secretase or reducing beta-amyloid 42 aggregation. Research examines these strategies and discusses ethical implications of immunization.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Context:
- The amyloid hypothesis of Alzheimer's disease (AD) pathogenesis, proposed in 1991, has spurred new therapeutic avenues.
- Traditional AD treatments focused on neurotransmitter levels, addressing neuronal loss effects.
- Emerging strategies aim to directly intervene in the neurodegenerative cascade.
Purpose:
- To review novel therapeutic strategies for Alzheimer's disease that target the underlying neurodegenerative process.
- To examine treatments involving secretase inhibitors and agents that reduce beta-amyloid 42 (Abeta42) aggregation.
- To discuss the clinical research landscape and ethical considerations of Abeta-targeted immunization.
Summary:
- Current Alzheimer's disease research focuses on therapies beyond neurotransmitter modulation.
- New approaches include secretase inhibitors and agents preventing beta-amyloid 42 (Abeta42) aggregation.
- The review analyzes Abeta42-related clinical studies and the ethical/economic aspects of Abeta immunization.
Impact:
- Shifts focus from symptomatic relief to disease modification in Alzheimer's disease therapy.
- Highlights the potential of targeting protein aggregation and processing pathways.
- Raises critical ethical and economic questions regarding the future of Alzheimer's immunization therapies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.